# A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age

> **NCT07478952** · PHASE1 · RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Epstein-Barr Virus

## Interventions

- **BIOLOGICAL:** mRNA-1189

## Key facts

- **NCT ID:** NCT07478952
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-05-15
- **Final completion:** 2027-05-15
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07478952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07478952, "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT07478952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*